On August 13, two pharmaceutical companies tied to the same cardiovascular research deal delivered major updates. Atrium Therapeutics, Inc. (NASDAQ:RNA) earned a $15 million milestone payment from Bristol-Myers Squibb Company (NYSE:BMY) after delivering a lead RNA compound targeting an undisclosed cardiology indication. The payment stems from a global collaboration eligible to yield Atrium up to $1.35 billion in R&D milestones, $825 million in commercial milestones, and low double-digit tiered royalties. Bristol Myers will fund all future clinical development and commercialization.
On the same day, Bristol Myers scored a major regulatory win: FDA accelerated approval for Zenbexus (iberdomide), the first approved CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for relapsed multiple myeloma. The contrast highlights two very different financial models in biotech: a high-burn clinical partner versus an established commercial giant.
Financial Comparison: Stability vs. High-Burn Clinical Pipeline
Comparing the two partners highlights vastly different scale and financial profiles. Bristol Myers reported Q2 2026 revenues of $12.97 billion, up 6% year-over-year (5% Ex-FX). Growth Portfolio sales surged 15% to $7.6 billion, driven by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, and Opdualag, offsetting a 4% decline in the Legacy Portfolio ($5.4 billion) due to generic competition. Non-GAAP EPS hit $2.04 (vs. $1.46 in Q2 2025), and GAAP EPS rose to $1.62. On the back of this performance, BMS raised its full-year 2026 revenue guidance to ~$49.0–$50.0 billion (up from $46.0–$47.5 billion) and increased its non-GAAP EPS outlook to $6.75–$7.00.
By contrast, clinical-stage Atrium generated $3.0 million in Q2 collaboration revenue (down from $3.85 million a year earlier) and posted a Q2 net loss of $20.18 million. While its H1 revenue rose to $22.6 million, Atrium remains unprofitable and reliant on non-dilutive milestone infusions. However, with $72.3 million in cash and $191.56 million in short-term investments, Atrium holds a solid $264 million capital cushion to fund pipeline advancement.
Bull and Bear Case
The bull case for Atrium Therapeutics, Inc. (NASDAQ:RNA) centers on its validated RNA delivery technology and deep-pocketed partners like Bristol Myers Squibb Company (NYSE:BMY) taking on clinical costs. The bear case stems from its lack of recurring product revenue, exposing shareholders to dilution or steep declines if pipeline candidates fail.
For Bristol-Myers Squibb Company (NYSE:BMY), the bull case is powered by its proven commercial engine and first-mover advantage with Zenbexus, alongside a second CELMoD candidate, mezigdomide, currently under FDA review with a PDUFA date of May 13, 2027. The bear case rests on patent cliffs for key commercial drugs and potential execution delays in replacing revenue fast enough.
Insider Monkey’s Hedge Fund Data Analysis
Insider Monkey’s hedge fund database shows diverging institutional sentiment between the two partners. Atrium Therapeutics experienced a sharp exit from institutional investors, with hedge fund holdings dropping from 69 funds in Q4 2025 to 37 funds in Q1 2026.
Conversely, Bristol-Myers Squibb Company maintained stable interest, held by 83 funds in Q1 2026 compared to 82 in Q4 2025. Cliff Asness’s AQR Capital Management holds over 27.35 million shares valued at $1.57 billion (-8% change), representing 0.55% of its portfolio. Richard S. Pzena’s Pzena Investment Management holds 17.00 million shares worth $979.9 million (-1% change), making up 2.88% of its portfolio.
Conclusion: What Investors Should Watch Next
Both companies enter the second half of 2026 with key operational catalysts ahead. Investors in Atrium Therapeutics, Inc. (NASDAQ:RNA) should watch for Phase 1/2 clinical readouts and further target selection milestones under the Bristol Myers collaboration. For Bristol-Myers Squibb Company (NYSE:BMY), investors should focus on the commercial launch trajectory of Zenbexus and regulatory progress for mezigdomide leading up to its 2027 PDUFA date.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
